Responses to Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation

Review of Responses to Systemic Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02827357

Enrollment

101

Registered

2016-07-11

Start date

2013-03-31

Completion date

2015-09-30

Last updated

2016-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

This chart review describe the response to systemic chemotherapy of patients with non-small cell lung cancer (NSCLC) harbouring a known somatic activating human epidermal growth factor receptor 2 (HER2) mutation. The analysis of this data will provide an initial description of the response to systemic chemotherapy in patients with NSCLC harboring an activating HER2 mutation in order to inform the design and powering of future randomized controlled clinical trials of HER2-directed therapy.

Interventions

OTHERNo specific intervention

Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with advanced nonsmall-cell lung cancer * known HER2 exon-20 insertion * treated with chemotherapy and/or HER2-targeted drugs

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame
Overall response rate	24 months

Secondary

Measure	Time frame
Median progression-free survival (PFS) with conventional chemotherapy	24 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026